Drugs / HTL0014242
HTL0014242
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04462263 | Jun 2020 → Jun 2021 | — | Nxera Pharma UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT03785054 | Nov 2018 → Mar 2021 | — | Nxera Pharma UK Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-01-05 | Nxera Pharma UK Limited | Regulatory Sosei Notes Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders nxera.life ↗ |
| 2023-01-05 | Nxera Pharma UK Limited | Regulatory Other nxera.life ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-01-05 | Nxera Pharma UK Limited | Sosei Notes Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders nxera.life ↗ |
| 2023-01-05 | Nxera Pharma UK Limited | Other nxera.life ↗ |
| 2018-12-13 | Nxera Pharma UK Limited | Sosei Heptares starts new clinical development program - First subject dosed in Phase I study of HTL0014242 nxera.life ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HTL0014242 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03785054 ↗ |
| Known as | CPD 25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3603923 ↗ |
| Known as | HTL14242 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3603923 ↗ |
| Modality | Small molecule | — CHEMBL3603923 ↗ |
| Route | Oral | “single oral doses of HTL0014242” NCT04462263 ↗ |